Evidence map›Paper›PMID 35699431›Full record

ArticleMicrobiology spectrum2022

PML Alternative Splice Products Differentially Regulate HAdV Productive Infection.

Julia Mai, Miona Stubbe, Samuel Hofmann, Sawinee Masser, Thomas Dobner, Christopher Boutell, Peter Groitl, Sabrina Schreiner

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The PML hub: An emerging actor of leukemia therapies.The Journal of experimental medicine · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Julia Mai *Institute of Virology, Hannover Medical School, Hannover, Germany.
Miona Stubbe *Institute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.
Samuel HofmannInstitute of Virology, Hannover Medical School, Hannover, Germany.
Sawinee MasserInstitute of Virology, Hannover Medical School, Hannover, Germany.
Thomas DobnerHeinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany.
Christopher BoutellMRC-University of Glasgow Centre for Virus Research (CVR), Glasgow, Scotland, United Kingdom.
Peter GroitlInstitute of Virology, School of Medicine, Technical University of Munich, Munich, Germany.
Sabrina SchreinerInstitute of Virology, Hannover Medical School, Hannover, Germany.
Technical University of Munich · DEHelmholtz Zentrum München · DELeibniz Institute of Virology (LIV) · DEMedizinische Hochschule Hannover · DEMRC University of Glasgow Centre for Virus Research · GB

Funding

Medical Research Council MC_UU_12014/5
6 · The paper itself

Abstract

Promyelocytic leukemia nuclear bodies (PML-NBs) were considered to maintain antiviral capacity, as these spherical complexes are antagonized by viruses. Actual work provides evidence, that PML-NB-associated factors might also be beneficial for distinct viral processes indicating why genomes and replication centers of nuclear replicating viruses are often found juxtaposed to PML-NBs. Several early HAdV proteins target PML-NBs, such as E4orf3 that promotes redistribution into track-like structures. PML-associated dependency factors that enhance viral gene expression, such as Sp100A remain in the nuclear tracks while restrictive factors, such as Daxx, are inhibited by either proteasomal degradation or relocalization to repress antiviral functions. Here, we did a comprehensive analysis of nuclear PML isoforms during HAdV infection. Our results show cell line specific differences as PML isoforms differentially regulate productive HAdV replication and progeny production. Here, we identified PML-II as a dependency factor that supports viral progeny production, while PML-III and PML-IV suppress viral replication. In contrast, we identified PML-I as a positive regulator and PML-V as a restrictive factor during HAdV infection. Solely PML-VI was shown to repress adenoviral progeny production in both model systems. We showed for the first time, that HAdV can reorganize PML-NBs that contain PML isoforms other then PML-II. Intriguingly, HAdV was not able to fully disrupt PML-NBs composed out of the PML isoforms that inhibit viral replication, while PML-NBs composed out of PML isoforms with beneficial influence on the virus formed tracks in all examined cells. In sum, our findings clearly illustrate the crucial role of PML-track formation in efficient viral replication.

Indexed as

Host-Pathogen InteractionsVirus ReplicationAntiviral AgentsHumansPromyelocytic Leukemia ProteinProtein IsoformsAntiviral AgentsPromyelocytic Leukemia ProteinProtein IsoformsHAdVhuman adenovirusPML-NBSUMO

Identifiers

PMID35699431
PMCPMC9431499
OpenAlexW4282927643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.